RepliCel Life Sciences Current ratio
Cos'è Current ratio di RepliCel Life Sciences?
Current ratio di RepliCel Life Sciences, Inc. è 0.24
Qual è la definizione di Current ratio?
Il rapporto corrente è un rapporto di liquidità che misura se una società dispone o meno di risorse sufficienti per soddisfare i suoi obblighi a breve termine.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio di aziende nel Health Care settore su TSXV rispetto a RepliCel Life Sciences
Cosa fa RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Aziende con current ratio simili a RepliCel Life Sciences
- Rochester Resources ha Current ratio di 0.24
- Africa ha Current ratio di 0.24
- Commonwealth Bank of Australia ha Current ratio di 0.24
- Fatfish Blockchain ha Current ratio di 0.24
- CBB ha Current ratio di 0.24
- Mimi's Rock ha Current ratio di 0.24
- RepliCel Life Sciences ha Current ratio di 0.24
- Code Chain New Continent ha Current ratio di 0.24
- Global Sweeteners ha Current ratio di 0.24
- WebSafety ha Current ratio di 0.24
- Lakes Oil NL ha Current ratio di 0.24
- Firm Capital Property Trust ha Current ratio di 0.24
- Burgundy Technology Acquisition ha Current ratio di 0.24